Nov 2024
MARIE showcased at MEDICA, Düsseldorf
.
Nov 2024
Innovative* Wearable Capnograph
1.5 g sensor and integrated oxygen therapy support
Ideal for
- Prehospital Care
- Emergency Care
- Procedural Sedation
* ) Pat. Pending
Overview
CO2 Sensor
Adapter
Mounted
Testimonials
”Being able to measure and monitor respiratory rate in a simple and technically reliable way with MARIE has the potential to save many patients’ lives. I see significant and important areas of application in healthcare for this medical product in the future.”
Anna Cedborg
Medical Doctor, PhD, Specialist in Anesthesiology & Intensive Care, Head of Clinic at Remeo, Stockholm, Sweden
Wearable Capnography
Meet MARIE™
MARIE™ (Mainstream Respiratory Infrared Equipment) is a wearable capnograph with integrated oxygen therapy support.
Team
Joakim Östblom
CEO
Anders Eckerbom
CTO
Pia Sundström
COO
Peter Karlsson
QA/RA Specialist
Gustav Hoppe
Head of QA/RA
Board of Directors
Lennart Käll (Chair)
Over 30 years of experience as a CEO and board member across various industries. Currently focused on board work, advisory roles to CEOs and boards, and managing personal investments.
Mikael Lönn
Medical doctor with over 40 years of experience as a business leader and entrepreneur in healthcare. Founder of M&M Medical and active investor with board roles in companies such as Genovis AB and Annexin Pharmaceuticals.
Helén Hedebark
Board member specializing in strategic business development and growth. Experienced in scaling B2B startups, M&A, and sustainability. Currently manages a Family Office and is an active business angel.
Anders Eckerbom
Over 40 years of experience in capnography and global OEM customers. Founder and R&D Director of Artema Medical and Phasein Medical, both successfully acquired by larger companies.
Joakim Östblom
Over 20 years of experience in R&D, sales, and marketing within Life Sciences. Successfully contributed to several product development projects and company acquisitions.
News & Updates
MARIE showcased at MEDICA, Düsseldorf
Feb 2025
MARIE’s first clinical trial completed at the ambulance
.
Feb 2025
Q1 2026
Expected FDA 510(k) clearance and CE-mark certification
.
Q1 2026
Contact
Oxlantic Medical AB, Ulls väg 29 C
756 51 Uppsala, Sweden
info@oxlantic.se